Comparing the outcomes of Capsaicin cream with mometasone cream in the treatment of Macular Amyloidosis

Comparing the outcomes of 0.025% Capsaicin cream with 0.1% mometasone cream in the treatment of Macular Amyloidosis lesions

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230307057646N3

Enrollment

Registered

2024-11-07

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular amyloidosis. Other amyloidosis

Interventions

Intervention 1: Intervention group: The first group will be treated with 0.025% capsaicin cream from Gol Daro Derman company for 4 months. Patients are examined two months, four months and six months

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age between 18-70 years no pregnancy and breastfeeding no use of other treatments such as tretinoin in the last month

Exclusion criteria

Exclusion criteria: pregnancy allergic or non-allergic reactions

Design outcomes

Primary

Measure	Time frame
Lesion size. Timepoint: two, four and six months after the start of the treatment. Method of measurement: The measurement is done using a millimeter ruler and will be reported as the area of ??the lesion.;Physician's satisfaction. Timepoint: two, four and six months after the start of the treatment. Method of measurement: To determine the recovery score, a doctor who is not aware of the patient's treatment process, examines the images taken before the start of the treatment as well as the images taken two months, four months and six months after the start of the treatment by seeing the images of the patients before and after the treatment. The treatment, clinical improvement rate and especially the pigmentation rate are graded on a scale of 1-10.;Patient's satisfaction. Timepoint: two, four and six months after the start of the treatment. Method of measurement: To check the level of satisfaction of the patients under treatment, the vas score (Visual Analogue Score) will be used as a criterion and will be announced as a score from 1-10. A score of one means no recovery and a score of ten means complete recovery from the patient's point of view.;Pruritus sensation in patients. Timepoint: two, four and six months after the start of the treatment. Method of measurement: The degree of itchiness of the lesions will be scored by the patient from 1-100, and 100 is the maximum itching and 1 is the complete disappearance of itching in the area of ??the lesions.	—

Measure

Time frame

Lesion size. Timepoint: two, four and six months after the start of the treatment. Method of measurement: The measurement is done using a millimeter ruler and will be reported as the area of ??the lesion.;Physician's satisfaction. Timepoint: two, four and six months after the start of the treatment. Method of measurement: To determine the recovery score, a doctor who is not aware of the patient's treatment process, examines the images taken before the start of the treatment as well as the images taken two months, four months and six months after the start of the treatment by seeing the images of the patients before and after the treatment. The treatment, clinical improvement rate and especially the pigmentation rate are graded on a scale of 1-10.;Patient's satisfaction. Timepoint: two, four and six months after the start of the treatment. Method of measurement: To check the level of satisfaction of the patients under treatment, the vas score (Visual Analogue Score) will be used as a criterion and will be announced as a score from 1-10. A score of one means no recovery and a score of ten means complete recovery from the patient's point of view.;Pruritus sensation in patients. Timepoint: two, four and six months after the start of the treatment. Method of measurement: The degree of itchiness of the lesions will be scored by the patient from 1-100, and 100 is the maximum itching and 1 is the complete disappearance of itching in the area of ??the lesions.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariba Iraji

Esfahan University of Medical Sciences

iraji@med.mui.ac.ir+98 31 3339 0100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026